Abstract
Tumour necrosis factor α (TNFα) blocking agents are among the most promising new treatments for rheumatoid arthritis (RA). However, no data exist about the effect of these agents on extra-articular manifestations of RA. A patient is described with small vessel vasculitis that repeatedly responded well to treatment with the soluble p55 TNFα receptor fusion protein Ro 45-2081 (lenercept).
Full Text
The Full Text of this article is available as a PDF (96.0 KB).
Figure 1 .
Before (A) and two weeks after (B) injection with lenercept (Ro 45-2081, an sTNFR:Fc p55 fusion protein). Small petechia and surrounding erythema are seen along the nailfold (A). After injection, the lesions are no longer present and the erythema has dramatically improved (B).